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Background: Pilocytic astrocytoma (PA) is a low-grade glioma that occurs primarily in 
children and young adults. The optimal postoperative treatment modality after subtotal 
resection (STR) of PAs remains to be elucidated. The aim of this study was to compare 
the efficacies of different post-STR treatment modalities and to examine the risk factors 
for the progression of PAs.
Methods: We reviewed the medical records of 91 pediatric PA patients in a single in-
stitute during a 30-year period. Kaplan-Meier analysis was used to assess overall survival 
(OS) and progression-free survival (PFS), and Cox proportional hazard models were used 
to calculate hazard ratios.
Results: The median age of 91 patients was 8.9 years (range, 0.3-17.9). GTR was per-
fomed, whenever possible. Patients who underwent STR afterwards received either ra-
diotherapy, chemotherapy, or were observed without further treatment, according to 
clinician preference. In total group, 10-year OS was 97.4% and 10-year PFS was 57.2%. 
In GTR group (N=33), 10-year OS and PFS was 100%. In STR group (N=49), 10-year 
OS was 97.7%, while 10-year PFS was 38.6%. STR group underwent following post-
operative (PO) modalities; observation (PO-Obs, N=32), radiotherapy (PO-RT, N=10), 
chemotherapy (PO-CTx, N=7). The 10-year PFS rate was higher in patients who received 
postoperative treatment (either PO-RT or PO-CTx) than in patients who received PO-Obs 
(62.5% vs 27.0%, P=0.039). In multivariate analysis for STR group, PO-CTx (Hazard ratio 
(HR)=0.20, P=0.035) and PO-RTx (HR=0.13, P=0.008) were superior to observation, 
respectively.
Conclusion: Radiation and chemotherapy are better post-STR treatment modalities than 
observation for pediatric PA patients.
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Introduction
Low-grade gliomas (LGGs) are a heterogeneous group of 
tumors of the central nervous system and include World 
Health Organization (WHO) grade I and grade II gliomas, 
such as astrocytomas, oligodendrogliomas, oligoas-
trocytomas, and mixed neuronal-glial tumors [1]. Low-grade 
astrocytomas (LGAs) include diffuse astrocytomas, pilomyx-
oid astrocytomas, and pleomorphic xanthoastrocytomas 
(WHO grade II), as well as pilocytic astrocytomas (PAs) and 
subependymal giant cell astrocytomas (WHO grade I). 
Although their clinical behavior can vary, the majority of 
LGGs are indolent and do not undergo malignant 
transformation. Thus, all LGGs were regarded as one entity 
in many reports.
PA is a slowly growing tumor that occurs primarily in 
children and young adults. It is the most common brain 
tumor in children aged 5-14 years and the second most 
common brain tumor in children aged 0-4 and 15-19 years, 
accounting for 20% of brain tumors in individuals under the 
age of 20 years and 30% of all posterior fossa tumors in 
childhood [2-4]. The cerebellum is the most common site 
of origin, particularly in children, although the entire neu-
raxis can be affected, such as the brain stem, optic tract, 
hypothalamus, spinal cord, and cerebral hemispheres [5,6]. 
Gross total resection (GTR), whenever possible, is the treat-
ment of choice and yields an excellent 5-year overall sur-
vival (OS) rate of 85-100% [6-10]. However, PAs arising in 
the optic pathway, brain stem, and hypothalamus are not 
usually amenable to GTR. In these cases, subtotal resection 
(STR) is typically performed in order to avoid complications 
such as visual field loss, third nerve palsy, endocrine defi-
cits, and death. However, STR results in less favorable out-
comes than does GTR. Fernandez et al., reported that GTR 
led to 5- and 10-year survival rates of 100% and recurrence 
rates of 2-5.4%, whereas 42-45% of partially removed have 
been demonstrated to recur [10]. The behavior of PA under-
went STR is unpredictable; recurrence can result in severe 
neurological deficits or death, while PAs rarely sponta-
neously regress after STR.
Clinicians dealing with PA patients face several di-
lemmas: which PAs will progress, whether postoperative 
first-line treatment is necessary, and whether the benefits 
of first-line treatment outweigh its side effects. There are 
no definite clinico-pathologic risk factors that predict out-
come after STR and no consensus regarding optimal treat-
ments after STR. Many authors recommend the 
“wait-and-see” policy, which is based on the premise that 
the residual tumor will remain silent for many years [4,11]. 
In previous reports, postoperative treatment after surgery 
improved progression-free survival (PFS) but not OS; how-
ever, most of these studies grouped pathologically hetero-
geneous LGGs and LGAs altogether, and various treatment 
strategies [12,13]. Therefore, the most effective treatment 
modality after STR remains to be elucidated [4]. Reoperation 
at the time of recurrence or progression is one treatment 
option; however, surgical morbidity and neurological com-
plications due to surgery or tumor progression per se are 
risk factors that must be considered [14]. Furthermore, the 
low success rate of GTR as the second operation can result 
in subsequent operations or multimodality treatment ap-
proaches [4].
Our goals were to determine the efficacy of radiotherapy, 
chemotherapy, and observation as postoperative treatment 
modalities after STR of pediatric PAs, to identify the risk 
factors for the progression of PAs, especially after STR, and 
to evaluate the general clinical characteristics of PAs and 
survival outcomes. To accomplish our aims, we performed 
a PA-specific retrospective study consisting of all tumor lo-
cations in a single institute, where a single group of clini-
cians decided the treatment modalities for each patient.
Materials and Methods
1) Patients
We carried out a retrospective study of 95 cases of pedia-
tric (defined as ＜18 years of age) PAs that occurred during 
a 30-year period (January 1983-December 2012) at Yonsei 
Cancer Center, Yonsei University Health System, Seoul, 
Korea. The revised WHO classification system was used to 
classify tumor type. All patients had pathologically con-
firmed PAs at the time of diagnosis or progression detected 
via either biopsy or surgery. Four cases of malignant trans-
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formation of PAs during follow-ups were not included in 
our analysis. The medical records of the remained 91 pa-
tients were reviewed for the following data: sex, age at di-
agnosis, tumor size, primary tumor location, presenting 
symptoms and signs, initial treatment modalities [GTR, STR, 
Gamma knife surgery (GKS), and observation], duration of 
follow-ups, and neurologic outcomes.
2) Treatment
GTR was performed if it would not result in significant 
neurologic deficits. GTR was defined as the removal of all 
tumor tissue during surgery and was approved only when 
both the surgeon’s report and postoperative neuroimaging 
were concordant.
When GTR was not feasible, STR or observation was 
chosen by a group of clinicians.
GKS was performed in cases presenting with small (＜3 
cm in size) tumors or with possibilities of neurologic com-
plications with other treatment modalities.
Patients treated via STR received the following post-
operative treatment modalities: radiation therapy (PO-RT), 
chemotherapy (PO-CTx), or closed observation (PO-Obs), 
as recommended by a group of clinicians. For PO-RT, local 
tumor fields plus a 1-2-cm margin received a median dose 
of 49.3 Gy (45.0-50.4 Gy) with a median daily fraction size 
of 1.8 Gy. PO-CTx patients usually received carboplatin 
and vincristine (CV) [15]; other patients received procarba-
zine, carboplatin, and vincristine (PCV).
3) Statistical analysis
OS was measured from the date of histologic diagnosis 
to the date of death or last contact with a surviving patient. 
PFS was measured from the date of diagnosis to the date 
of the first failure of any type, death, or last contact with 
a patient who had responded. The Kaplan-Meier method 
was used to estimate OS and PFS rates. Survival estimates 
were compared via the log rank test. The Cox proportional 
hazards regression model was used for survival analyses of 
clinical variables such as age at diagnosis. All analyses were 
performed using SPSS software, version 21 (SPSS Inc., 
Chicago, IL, USA), and a P-value of ＜0.05 was considered 
statistically significant.
4) Ethics statement
This study was approved by the institutional review 
board of Severance Hospital (IRB No. 4-2014-0512).
Results
1) Patient demographics
The male-to-female ratio was 0.9 and the median age at 
diagnosis of PA was 8.9 years (range, 0.3-17.9) (Table 1). 
Among our 91 pediatric PA patients, 24 (26.4%) were 
younger than 5 years of age.
The main presenting symptoms were headache (65.9%), 
vomiting (28.5%), gait disturbance (22.0%), visual dis-
turbance (18.6%) and seizure (6.5%). Incidental PAs were 
found in two cases after traumatic head injury. Regarding 
to treatment modalities, 82 (90%) received surgery as their 
initial treatment; 33 received GTR and 49 received STR. 
Three patients (3.3%) received GKS, and 6 (6.6%) were 
observed. During the follow-up period, 88 patients under-
went 113 surgeries; once (N=69), twice (N=13), 3 times 
(N=6). During the follow-up period, 12 patients received 
GKS, 15 patients received RT, and 12 patients received a 
total of 13 cycles of chemotherapies. The chemotherapy 
regimens were as follows: CV (N=5), PCV (N=5), vinblas-
tine, etoposide, 5-flurouracil and cyclophosphamide (N=3) 
[16].
2) OS and PFS in total group 
At a median follow-up duration of 92 months (range, 
4-302 months), 88 (96.7%) patients were alive, and 59 
(63.4%) patients were progression-free. The 10-year OS and 
PFS estimates were 97.4±1.8% and 57.2±6.1%, re-
spectively (Fig. 1). Three patients died during follow-up; 
as a result of tumor progression (N=1), perioperative shock 
(N=1) and bacterial meningitis related with ventriculo-peri-
toneal shunt (N=1).
3) OS and PFS on the basis of initial treatment modalities 
in total group
The 10-year OS rates for the initial treatment modalities 
were as follows: GTR, 100%; STR, 97.7±2.3%; GKS, 100%; 
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Table 1. Patient demographics (N=91)
Factors Total (N=91) Age＜5 (N=24) 5≤Age＜18 (N=67) P-value
Sexa)
  Male
  Female
Tumor size (cm)b)
Locationa)
  Cerebellar
  Supratentorial
  Brain stem
  Suprasellar
  Optic tract
  Spinal cord
  Thalamus
Treatment modalities (N)c)
  Surgery
    GTR
    STR
  GKS
  Radiotherapy
  Chemotherapy
10-year OS (%)d) 
10-year PFS (%)d)
Endocrinal dysfunctiona)
Follow up (years)b)
 
  43 (47.3)
  48 (52.7)
 
 
  45 (49.5)
  12 (13.2)
  8 (8.8)
  7 (7.7)
  14 (15.4)
  2 (2.2)
  3 (3.3)
 
113
 34
 79
 12
 15
 12
97.4±1.8
57.2±6.1
  6 (6.6)
7.8±6.5 (0.3-25.2)
 
  11 (45.8)
  13 (54.2)
4.4±2.1 (1.0-8.0)
 
  12 (50.0)
  1 (4.2)
  1 (4.2)
   3 (12.5)
   7 (29.2)
  0 (0.0)
  0 (0.0)
 
 
 
 
 
 
 
90.0±6.7
 41.8±11.5
  1 (4.2)
 
 
32 (47.8)
35 (52.2)
4.0±1.4 (1.0-6.0)
 
33 (49.3)
11 (16.4)
7 (10.4)
4 (6.0)
7 (10.4)
2 (3.0)
3 (4.5)
 
 
 
 
 
 
 
100.0±0.0
63.3±7.0
5 (7.5)
 
0.531
 
 
0.255
0.142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.005
0.043
0.497
 
GKS, gamma knife surgery; GTR, gross total resection; N, numbers; OS, overall survival; PFS, progression free survival; STR, subtotal 
resection.
a)data were shown as numbers (%). b)data were shown as mean±standard deviations (range). c)data included all numbers of treatment 
during follow-up. d)data were shown as mean±standard errors.
Fig. 1. Overall Survival and Progression Free Survival in total 
group (N=91).
and observation, 83.3±15.2% (P=0.081) (Fig. 2A). This re-
sult showed the tendency that GTR was superior to STR 
or observation, but did not reach to statistical significance 
due to small number of deaths (N=3). The 10-year PFS rates 
were as follows: GTR, 100%; STR, 38.6±8.0%; GKS, 
50.0±35.4% and observation 16.7±15.2% (P＜0.001) (Fig. 
2B). No patients in the GKS group died, but 1 (33%) experi-
enced disease progression. In the observation group, 5 
(83.3%) patients progressed including 1 (16.7%) who died. 
In the STR group, 28 (57.1%) patients progressed including 
2 (4.1%) who died.
4) OS and PFS on the basis of tumor locations in total group 
The 10-year OS rates on the basis of primary tumor sites 
were as follows: optic tract, 92.3±7.4%; suprasellar region, 
75.0±21.7%; and brain stem 50.0±35.4% (P=0.050) There 
were no deaths in cases of cerebellar, supratentorial, thalamic, 
or spinal cord tumors. The 10-year PFS rates were as follows: 
cerebellum, 69.1±7.6; supratentorial region, 72.0±17.8%; 
brain stem, 51.4±20.4%; suprasellar, 34.3±19.5%; and optic 
tract, 23.2±11.7% (P=0.006). The mean time to progression 
was significantly lower in suprasellar (5.6 years) and optic 
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Fig. 2. Overall Survival and Progression Free Survival by Clinical Parameters in total group (N=91). (A) Overall Survival by initial
treatment modalities. (B) Progression Free Survival by initial treatment modalities.
Table 2. Clinical parameters affecting the choice of initial treatment modalities in total group (N=91)
GTR (N=33) STR (N=49) GKS (N=3) Observation (N=6) P-value
Age (year)a)
Tumor size (cm)a)
Tumor locationb)
  Cerebellar
  Supratentorial 
  Brain stem 
  Suprasellar 
  Optic tract 
  Spinal cord 
  Thalamus
10.0±4.8 (2.4-17.9)
4.2±1.7 (1.0-8.0)
 
22 (48.9)
7 (58.3)
1 (12.5)
1 (14.3)
0 (0.0)
1 (50.0)
1 (33.3)
8.3±4.4 (0.9-17.5)
4.1±1.8 (1.0-8.0)
 
23 (51.1)
4 (33.3)
5 (62.5)
5 (71.4)
10 (71.4)
1 (50.0)
1 (33.3)
14.4±2.4 (12.5-17.1)
3.0±0.0 (3.0-3.0)
 
0 (0.0)
1 (8.3)
0 (0.0)
0 (0.0)
1 (7.1)
0 (0.0)
1 (33.3)
4.8±4.6 (0.4-11.6)
2.2±1.8 (0.5-7.0)
 
0 (0.0)
0 (0.0)
2 (25.0)
1 (14.3)
3 (21.4)
0 (0.0)
0 (0.0)
0.009
0.082
0.003
 
 
 
 
 
 
 
GKS, gamma knife surgery; GTR, gross total resection; STR, subtotal resection.
a)data was shown as mean±standard deviations (range). b)data was shown as numbers (%).
tract tumors (4.2 years) than in tumors at other sites (11.3 
years). 
5) OS and PFS on the basis of age at diagnosis in total group 
The 10-year OS rates of the age groups were as follows: 
＜5 years, 90.0±6.7%; 5 to ＜18 years, 100 (P=0.005). The 
10-year PFS rates were as follows: ＜5 years, 41.8±11.5%; 
5 to ＜18 years, 63.3±7.0% (P=0.043).
6) Clinical parameters affecting the choice of initial treatment 
modalities in total group 
Tumor location was related to the choice of initial treat-
ment modalities (P=0.003) (Table 2). Cerebellar tumors and 
supratentorial tumors were treated via GTR the most fre-
quently, whereas tumors in the brain stem, suprasellar re-
gion, or optic tract were primarily treated via STR. Age was 
also related to the choice of initial treatment modalities. 
The median age was oldest in GKS group, and youngest 
in observation group (P=0.009). The tumor size was smaller 
in the observation group than in the GTR and STR groups 
However, this did not reach to statistical significance 
(P=0.082). 
7) PFS on the basis of postoperative treatment modalities 
in the STR group
In STR group (N=49), 10-year-OS was good as 97.7%, but 
10-year-PFS was low as 38.6% The 10-year PFS rates on the 
basis of postoperative treatment modalities were 71.1%, 
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Fig. 3. Progression free survival comparison between treatment group and observation group in subtotal resected patients (N=49). 
(A) Progression Free Survival by postoperative treatment modalities in STR group. (B) Comparison of progression free survival between
treatment group and observation group after STR. PO-CTx, postoperative chemotherapy; PO-Obs, observation after operation; PO-RT,
postoperative radiotherapy.
Table 3. Clinical parameters affecting the choice of postoperative treatment modalities in STR group (N=49)
PO-Obs (N=32) PO-RT (N=10) PO-CTx (N=7) P-value
Age (year)a)
Tumor size (cm)a)
Tumor locationb)
  Cerebellar, N=23 (46.9)
  Supratentorial, N=4 (8.2)
  Brain stem, N=5 (10.2)
  Suprasellar, N=5 (10.2)
  Optic tract, N=10 (20.4)
  Spinal cord, N=1 (2.0)
  Thalamus, N=1 (2.0)
8.0±4.7 (0.9-17.0)
4.3±1.6 (1.5-8.0)
 
19 (82.6)
3 (75.0)
2 (40.0)
3 (60.0)
4 (40.0)
0 (0.0)
1 (100.0)
8.4±3.0 (3.7-12.9)
3.1±1.0 (2.0-5.0)
 
2 (8.7)
0 (0.0)
3 (60.0)
0 (0.0)
4 (40.0)
1 (100.0)
0 (0.0)
10.0±4,8 (2.1-17.5)
4.3±2.5 (1.0-8.0)
 
2 (8.7)
1 (25.0)
0 (0.0)
2 (40.0)
2 (20.0)
0 (0.0)
0 (0.0)
0.553
0.305
0.039
 
 
 
 
 
 
 
PO-CTx, postoperative chemotherapy; PO-Obs, observation after operation; PO-RT, postoperative radiotherapy.
a)data was shown as mean±standard deviations (range). b)data was shown as numbers (%).
53.6%, and 27.0% for the PO-RT, PO-CTx, and PO-Obs, re-
spectively (P=0.089) (Fig 3A). The 10-year PFS rate was 
higher in patients who received postoperative treatment 
(either PO-RT or PO-CTx) after STR (62.5%) than in patients 
who received PO-Obs (27.0%; P=0.039) (Fig. 3B).
8) Clinical parameters affecting the choice of postoperative 
treatment modalities in the STR group
Tumors in cerebellar and supratentorial lesions were 
more commonly observed without further treatment after 
STR, whereas deep-seated tumors were more frequently 
treated after STR rather than just observed (P=0.039) (Table 
3). Age and tumor size did not affect the choice of post-
operative treatment modalities.
9) Prognostic factors determined by a multivariate analysis 
of PFS in the STR group 
In a multivariate analysis of PFS in the STR group 
(N=49), postoperative treatments were favorable factors 
(PO-RT: HR, 0.13; 95% CI, 0.03-0.59; P=0.008; PO-CTx: HR, 
0.20; 95% CI, 0.46-0.90; P=0.035) (Table 4). Suprasellar 
(HR, 7.54; 95% CI, 1.55-36.59; P=0.012) and optic tract tu-
mors (HR, 5.71; 95% CI, 1.62-20.08, P=0.007) were poor 
prognostic factors. Age and sex were not prognostic factors 
for progression.
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Table 4. Prognostic factors determined by a multivariate 
analysis of PFS in the STR group (N=49)
Hazard 
ratio
95% 
Confidence 
interval
P-value
Postoperative treatment modalities
  PO-Obs
  PO-RT
  PO-CTx
Location
  Cerebellar
  Supratentorial
  Brain stem
  Suprasellar
  Optic tract
  Spinal cord
  Thalamus
Age
  5≤Age＜18
  Age＜5
Sex
  Male
  Female
 
1
0.13
0.20
 
1
1.33
0.62
7.54
5.71
3.36
1.18
 
1
1.74
 
1
1.16
 
 
0.03-0.59
0.46-0.90
 
 
0.35-5.13
0.08-4.94
 1.55-36.59
 1.62-20.08
 0.35-32.13
0.13-9.31
 
 
0.68-4.48
 
 
0.40-3.31
 
 
0.008a)
0.035a)
 
 
0.679
0.651
0.012b)
0.007b)
0.293
0.919
 
 
0.250
 
 
0.786
PO-CTx, postoperative chemotherapy; PO-Obs, observation 
after operation; PO-RT, postoperative radiotherapy.
a)stastically significant good prognostic factors. b)stastically 
significant poor prognostic factors.
10) Endocrine dysfunction
Permanent endocrine dysfunction was occurred in six 
(6.6%) patients; panhypopituitarism (N=2), combined growth 
hormone and sexual hormone (luteinizing hormone and fol-
licular stimulating hormone) deficiencies (N=2), pure growth 
hormone deficiency (N=1), and adrenocorticotropic hor-
mone deficiency (N=1). Tumor locations were related with 
endocrine dysfunctions (P=0.039). Five of 31 (16.1%) deep 
located tumors showed endocrinal dysfunction; brain stem 
(N=2), suprasellar (N=2) and optic tract (N=1). One of 57 
(1.7%) superficial tumors (included cerebellar and supra-
tentorial) showed endocrine dysfunction. No endocrine dys-
function was occurred in 3 spinal tumors. Treatment modal-
ities were not related with endocrine dysfunction, maybe 
due to insufficient number of events. One of six had received 
GTR, while other five patients received STR (P=0.502). 
Postoperative treatment after STR did not affect permanent 
endocrine dysfunction; 3 of 32 (9.3%) in PO-Obs group, 1of 
10 (10%) PO-RT group, and 1 of 7 (14.3%) PO-CTx group 
(P=0.210). Age was not related with endocrine dysfunction.
Discussion
PAs are slowly growing WHO grade I tumors, which are 
generally associated with favorable prognosis. They ac-
count for approximately 15-20% of pediatric brain tumors 
[2,3], and commonly occur in the first two decades of life 
[5,17,18]. Our study included 91 pediatric PA patients, of 
which 24 (26.4%) were under the age of five. Tumor loca-
tions and clinical symptoms were not different between age 
groups. In our study, cerebellar tumors were the most prev-
alent location of PAs (49.5%), followed by the optic tract, 
supratentorial and brain stem.
Several studies have shown that the extent of resection 
is a main prognostic factor [6-10,19]. Our study also showed 
the importance of initial treatment modalities. Aggressive 
surgery (e.g., GTR) is the best approach for halting tumor 
progression and extending survival (7). After GTR, the next 
step is routine follow-up. Our Study showed no recurrence 
or death after GTR. Compared with patients receiving sur-
gery, patients whose initial treatment modality was ob-
servation had the worst outcomes in our study; their 10-year 
OS and PFS rate was 83.3% and 16.7%, respectively. 
Observation is typically chosen for PAs in locations not read-
ily accessible, such as the brain stem and optic tract.
Tumor locations are also prognostic factors for PA, main-
ly because they are related to the extent of resection 
[4,6,10,17]. Tumors in deep locations, where GTR is not 
feasible, have a worse prognosis than do tumors in more 
superficial locations [6,17]. In our study, brain stem, supra-
sellar, optic tract tumors were associated with tumor pro-
gression and reduced survival.
Age at diagnosis was a prognostic factor in some studies. 
LGG patients less than 5 or 7 years of age had an un-
favorable prognosis [7,10].We found that an age less than 
5 years was an unfavorable prognostic factor for both OS 
and PFS.
To treat or observe after STR is the one of the most per-
plexing problems to clinicians. Many authors recommend 
the “wait-and-see” policy, which means treatment only after 
re-progression of the PA and is based on the premise that 
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OS will be unaffected regardless of whether PFS sig-
nificantly improves [4,20]. Although the OS rates were not 
statistically different between the treatment modalities in 
our study, longer PFS times are important. Tumor pro-
gression can result in significant neurologic morbidities [14], 
and shorter PFS times, especially in patients with brain tu-
mors, negatively affect the quality of life of both patients 
and caregivers [21].
There had been many debates on the management of 
LGGs including PAs. Jakola et al. showed that early surgical 
resection improved survival compared with a “biopsy and 
watchful waiting strategy” [22]. Other reports of LGGs 
showed the efficacy of postoperative treatment for pro-
gression free survival benefit. The 1996 Hirntumorstudien 
study of pediatric WHO grade 1 and 2 gliomas showed that 
PO-RT and PO-CTx improved PFS rates and role of PO-CTx 
for deferred RT [13]. However, these studies had limitations 
that apply directly to PA patients who underwent STR pa-
tients as in our study. Many studies grouped heterogeneous 
pathologies such as LGGs or LGAs together and analyzed 
the efficacy of all treatment modalities together regardless 
of the clinical situation (e.g., initial, postoperative, or sal-
vage treatment) or the extent of surgery, which is the most 
important prognostic factor for survival and progression. In 
addition, some reports only examined specific age groups 
or specific tumor locations, for example, the cerebellum, 
where GTR is usually amenable and thus the efficacy of 
the postoperative treatment is diminished. 
Our study was limited to PAs and focused on patients 
who underwent STR. It compared the effects of post-
operative treatment and observation just after STR, which 
is an unsolved problem among clinicians and patients. 
Post-STR treatment (PO-RT or PO-CTx) showed an approx-
imate 35% benefit in PFS compared with PO-Obs. This 
means that 35% of patients remained progression-free for 
several years, which prevented further potential neurologic 
complications. Thus, for residual tumors after surgery, treat-
ment appears to be a better option rather than observation.
Neurocognitive dysfunction and endocrine dysfunction 
are considerable factors, which could be related with tumor 
progression per se or treatment related toxicity [23]. Our 
study showed that treatment modalities after STR did not 
affect endocrine dysfunction, while tumor locations did. 
However, we could not suggest that whether PO-RT or 
PO-CTx do not affect endocrine dysfunction in our study, 
due to insufficient numbers of endocrine dysfunctions.
Our study had limitations. Although our cohort was rela-
tively large for a single institute, which has homogenous 
treatment policies, our study is retrospective, and may have 
selection bias. And neurocognitive function was not eval-
uated fully in our study.
Nevertheless, it had strengths including its restriction to 
PA pathology, its focus on patients who underwent STR, 
and its inclusion of all tumor locations and all age groups 
of pediatric patients. In conclusion, postoperative treatment 
(either PO-RT or PO-CTx) after STR of PAs can prolong 
PFS, which will improve the patients’ quality of life.
Acknowledgements
The authors would like to thank Dong-Su Jang, MFA, 
(Medical Illustrator, Medical Research Support Section, 
Yonsei University College of Medicine, Seoul, Korea) for his 
help with the illustrations.
References
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO 
Classification of tumours of the central nervous system, 4th 
ed. Geneva: IARC, 2007.
2. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical 
report: Primary brain and central nervous system tumors diag-
nosed in the United States in 2006-2010. Neuro Oncol 2013;15 
Suppl 2:ii1-56.
3. Kaatsch P, Rickert CH, Kuhl J, Schuz J, Michaelis J. 
Population-based epidemiologic data on brain tumors in 
German children. Cancer 2001;92:3155-64.
4. Dirven CM, Mooij JJ, Molenaar WM. Cerebellar pilocytic as-
trocytoma: a treatment protocol based upon analysis of 73 
cases and a review of the literature. Childs Nerv Syst 1997;13: 
17-23.
5. Malik A, Deb P, Sharma MC, Sarkar C. Neuropathological 
spectrum of pilocytic astrocytoma: an Indian series of 120 
cases. Pathol Oncol Res 2006;12:164-71.
6. Paixao Becker A, de Oliveira RS, Saggioro FP, Neder L, 
Chimelli LM, Machado HR. In pursuit of prognostic factors 
in children with pilocytic astrocytomas. Childs Nerv Syst 2010; 
26:19-28.
 Radiation or Chemotherapy for Subtotally Resected Pilocytic Astrocytoma
Clin Pediatr Hematol Oncol    103
7. Gajjar A, Sanford RA, Heideman R, et al. Low-grade as-
trocytoma: a decade of experience at St. Jude Children's 
Research Hospital. J Clin Oncol 1997;15:2792-9.
8. Desai KI, Nadkarni TD, Muzumdar DP, Goel A. Prognostic 
factors for cerebellar astrocytomas in children: a study of 102 
cases. Pediatr Neurosurg 2001;35:311-7.
9. Due-Tonnessen BJ, Helseth E, Scheie D, Skullerud K, Aamodt 
G, Lundar T. Long-term outcome after resection of benign 
cerebellar astrocytomas in children and young adults (0-19 
years): report of 110 consecutive cases. Pediatr Neurosurg 
2002;37:71-80.
10. Fernandez C, Figarella-Branger D, Girard N, et al. Pilocytic 
astrocytomas in children: prognostic factors-a retrospective 
study of 80 cases. Neurosurgery 2003;53:544-53; discussion 
554-5.
11. Mandiwanza T, Kaliaperumal C, Khalil A, Sattar M, Crimmins 
D, Caird J. Suprasellar pilocytic astrocytoma: one national 
centre's experience. Childs Nerv Syst 2014.
12. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy 
of early versus delayed radiotherapy for low-grade as-
trocytoma and oligodendroglioma in adults: the EORTC 22845 
randomised trial. Lancet 2005;366:985-90.
13. Gnekow AK, Falkenstein F, von Hornstein S, et al. Long-term 
follow-up of the multicenter, multidisciplinary treatment study 
HIT-LGG-1996 for low-grade glioma in children and adoles-
cents of the German Speaking Society of Pediatric Oncology 
and Hematology. Neuro Oncol 2012;14:1265-84.
14. Bowers DC, Krause TP, Aronson LJ, et al. Second surgery for 
recurrent pilocytic astrocytoma in children. Pediatr Neurosurg 
2001;34:229-34.
15. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine 
for recurrent and newly diagnosed low-grade gliomas of 
childhood. J Clin Oncol 1993;11:850-6.
16. Cho BK, Jung HL, Ghim TT, et al. KSPNO protocol for 
glioma. Korean J Pediatr Hematol Oncol 2005;12:244-85.
17. Cyrine S, Sonia Z, Mounir T, et al. Pilocytic astrocytoma: a 
retrospective study of 32 cases. Clin Neurol Neurosurg 2013; 
115:1220-5.
18. Theeler BJ, Ellezam B, Sadighi ZS, et al. Adult pilocytic as-
trocytomas: clinical features and molecular analysis. Neuro 
Oncol 2014;16:841-7.
19. Pencalet P, Maixner W, Sainte-Rose C, et al. Benign cerebellar 
astrocytomas in children. J Neurosurg 1999;90:265-73.
20. Gupta N, Banerjee A, Haas-Kogan D. Pediatric CNS tumors. 
Springer, 2010;1-35.
21. Lamperti E, Pantaleo G, Finocchiaro CY, et al. Recurrent brain 
tumour: the impact of illness on patient's life. Support Care 
Cancer 2012;20:1327-32.
22. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strat-
egy favoring early surgical resection vs a strategy favoring 
watchful waiting in low-grade gliomas. JAMA 2012;308:1881-8.
23. Kortmann RD, Timmermann B, Taylor RE, et al. Current and 
future strategies in radiotherapy of childhood low-grade glio-
ma of the brain. Part II: Treatment-related late toxicity. 
Strahlenther Onkol 2003;179:585-97.
